After 37 years, this biotech nears a first drug approval in breast cancer

After 37 years, this biotech nears a first drug approval in breast cancer

STAT Plus: After 37 years of trying, this biotech nears a first drug approval in breast cancer

By ADAM FEUERSTEIN

NATIONAL CANCER INSTITUTE/UNIV. OF PITTSBURG CANCER INSTITUTE

On Friday, the FDA is expected to reveal its decision on Immunomedics' antibody drug conjugate to treat triple-negative breast cancer.

READ MORE